ENDRA Life Sciences Inc.
NDRA
$5.50
-$0.42-7.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.02% | -2.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.35% | -11.45% | |||
| Operating Income | -5.35% | 11.45% | |||
| Income Before Tax | -30.19% | -18.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.19% | -18.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.19% | -18.30% | |||
| EBIT | -5.35% | 11.45% | |||
| EBITDA | -5.28% | 11.25% | |||
| EPS Basic | -22.64% | 8.02% | |||
| Normalized Basic EPS | -22.64% | 8.01% | |||
| EPS Diluted | -22.64% | 8.02% | |||
| Normalized Diluted EPS | -22.64% | 8.01% | |||
| Average Basic Shares Outstanding | 6.15% | 28.60% | |||
| Average Diluted Shares Outstanding | 6.15% | 28.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||